实用临床医药杂志
實用臨床醫藥雜誌
실용림상의약잡지
JOURNAL OF JIANGSU CLINICAL MEDICINE
2014年
16期
120-122
,共3页
尹小祥%刘阳晨%周绍兵%古亮
尹小祥%劉暘晨%週紹兵%古亮
윤소상%류양신%주소병%고량
老年%食管癌%同步放化疗
老年%食管癌%同步放化療
노년%식관암%동보방화료
the elderly%esophageal cancer%concurrent chemoradiotherapy
目的:评价同步放化疗在老年食管癌治疗中的应用价值。方法87例老年食管癌患者随机分为同步放化疗组(42例)和单独放疗组(45例),随访2组临床疗效及毒副反应。结果同步放化组和单放组的总有效率(CR+PR)分别为92.9%、77.8%,2组比较差异有统计学意义(P <0.05);同步放化组和单放组的12年生存率分别为85.7%、59.5%,66.7%、37.8%,生存率比较差异有统计学意义(P <0.05);同步放化疗组的毒副反应高于单独放疗组(P <0.05)。结论同步放化疗能提高老年食管癌患者总有效率及1、2年生存率,但亦显著增加了放疗副反应。
目的:評價同步放化療在老年食管癌治療中的應用價值。方法87例老年食管癌患者隨機分為同步放化療組(42例)和單獨放療組(45例),隨訪2組臨床療效及毒副反應。結果同步放化組和單放組的總有效率(CR+PR)分彆為92.9%、77.8%,2組比較差異有統計學意義(P <0.05);同步放化組和單放組的12年生存率分彆為85.7%、59.5%,66.7%、37.8%,生存率比較差異有統計學意義(P <0.05);同步放化療組的毒副反應高于單獨放療組(P <0.05)。結論同步放化療能提高老年食管癌患者總有效率及1、2年生存率,但亦顯著增加瞭放療副反應。
목적:평개동보방화료재노년식관암치료중적응용개치。방법87례노년식관암환자수궤분위동보방화료조(42례)화단독방료조(45례),수방2조림상료효급독부반응。결과동보방화조화단방조적총유효솔(CR+PR)분별위92.9%、77.8%,2조비교차이유통계학의의(P <0.05);동보방화조화단방조적12년생존솔분별위85.7%、59.5%,66.7%、37.8%,생존솔비교차이유통계학의의(P <0.05);동보방화료조적독부반응고우단독방료조(P <0.05)。결론동보방화료능제고노년식관암환자총유효솔급1、2년생존솔,단역현저증가료방료부반응。
Objective To evaluate the efficacy of capecitabine and nedaplatin combined with chemoradiotherapy in the treatment of the elderly patients with esophageal cancer.Methods 87 patients were randomly divided into concurrent chemoradiotherapy group(42 patients)and radio-therapy group(45 patients).The chemoradiotherapy group was treated with concurrent radiothera-py combined with chemotherapy while the radiotherapy group was treated with radiotherapy only. Results The overall efficacy (CR+PR)rates of concurrent chemoradiotherapy group and control group were 92.9% and 77.8,the difference was significant between the two groups(P <0.05). The survival rate of concurrent group after 1 year and 2 years was higher than that in the control group (85.7%,59.5% in 1 year vs 66.7%,37.8% in 2 years respectively).And the difference in toxicity was significant between the two groups with higher toxicity in the concurrent chemoradio-therapy group than in the control group (P <0.05).Conclusion The concurrent chemoradiother-apy in the treatment of the elderly with esophageal cancer can improve the overall efficacy rates and 1,2 year survival rates,but the toxicity was significantly higher.